TNF-α inhibitor tanfanercept (HBM9036) improves signs and symptoms of dry eye in a phase 2 trial in the controlled adverse environment in China

被引：0
作者：
Yanling Dong
Shuang Wang
Lin Cong
Ting Zhang
Jun Cheng
Nannan Yang
Xiaohong Qu
Dongfang Li
Xueying Zhou
Holly Wang
Michael Lee
Meng Wang
Stephen Chen
George W. Ousler
Xiaoxiang Chen
Lixin Xie
机构：
[1] State Key Laboratory Cultivation Base,Qingdao Eye Hospital of Shandong First Medical University
[2] Shandong Provincial Key Laboratory of Ophthalmology,undefined
[3] Eye Institute of Shandong First Medical University,undefined
[4] Harbour BioMed,undefined
[5] Ora Inc,undefined
来源：
International Ophthalmology | 2022年 / 42卷
关键词：
Dry eye disease; TNF-TNFR1 inhibitor; Tanfanercept; Controlled adverse environment;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2459 / 2472
页数：13
相关论文
共 8 条
  • [1] TNF-α inhibitor tanfanercept (HBM9036) improves signs and symptoms of dry eye in a phase 2 trial in the controlled adverse environment in China
    Dong, Yanling
    Wang, Shuang
    Cong, Lin
    Zhang, Ting
    Cheng, Jun
    Yang, Nannan
    Qu, Xiaohong
    Li, Dongfang
    Zhou, Xueying
    Wang, Holly
    Lee, Michael
    Wang, Meng
    Chen, Stephen
    Ousler, George W.
    Chen, Xiaoxiang
    Xie, Lixin
    INTERNATIONAL OPHTHALMOLOGY, 2022, 42 (08) : 2459 - 2472
  • [2] Exacerbation of signs and symptoms of allergic conjunctivitis by a controlled adverse environment challenge in subjects with a history of dry eye and ocular allergy
    Gomes, Paulo J.
    Ousler, George W.
    Welch, Donna L.
    Smith, Lisa M.
    Coderre, Jeffrey
    Abelson, Mark B.
    CLINICAL OPHTHALMOLOGY, 2013, 7 : 157 - 165
  • [3] Association of Conjunctival Cell HLA-DR Expression with the Severity of Signs and Symptoms of Dry Eye Disease at Baseline in the NORTHERN LIGHTS Phase 2 Trial
    Kuklinski, Eric J.
    Roy, Neeta S.
    Praestegaard, Morten
    Wei, Yi
    Asbell, Penny A.
    CURRENT EYE RESEARCH, 2025,
  • [4] Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE (TM)) model
    Sosne, Gabriel
    Ousler, George W.
    CLINICAL OPHTHALMOLOGY, 2015, 9 : 877 - 884
  • [5] SkQ1 Ophthalmic Solution for Dry Eye Treatment: Results of a Phase 2 Safety and Efficacy Clinical Study in the Environment and During Challenge in the Controlled Adverse Environment Model
    Anton Petrov
    Natalia Perekhvatova
    Maxim Skulachev
    Linda Stein
    George Ousler
    Advances in Therapy, 2016, 33 : 96 - 115
  • [6] SkQ1 Ophthalmic Solution for Dry Eye Treatment: Results of a Phase 2 Safety and Efficacy Clinical Study in the Environment and During Challenge in the Controlled Adverse Environment Model
    Petrov, Anton
    Perekhvatova, Natalia
    Skulachev, Maxim
    Stein, Linda
    Ousler, George
    ADVANCES IN THERAPY, 2016, 33 (01) : 96 - 115
  • [7] Efficacy and Safety of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease The ONSET-2 Phase 3 Randomized Trial
    Wirta, David
    Vollmer, Patrick
    Paauw, James
    Chiu, Kuei-Hsun
    Henry, Eugenia
    Striffler, Kristen
    Nau, Jeffrey
    OPHTHALMOLOGY, 2022, 129 (04) : 379 - 387
  • [8] ONSET-1 Phase 2b Randomized Trial to Evaluate the Safety and Efficacy of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease
    Wirta, David
    Torkildsen, Gail L.
    Boehmer, Blair
    Hollander, David A.
    Bendert, Edward
    Zeng, Lijuan
    Ackermann, Michael
    Nau, Jeffrey
    CORNEA, 2022, 41 (10) : 1207 - 1216
1